GMAB

Rinatabart sesutecan (Rina-S), an investigational folate receptor-alpha (FRα)-targeted, Topo1 antibody-drug conjugate, demonstrated promising anti-tumor activity in a Phase 1/2 clinical trial for heavily pretreated patients with ovarian and endometrial cancers.

Genmab A/S, a biotechnology company, announced that its CEO and CFO will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference on September 4, 2024.

Genmab A/S, a biotechnology company, disclosed transactions in its shares made by its managerial employees and their closely associated persons.

Genmab A/S, a biotechnology company, announced an increase in its share capital by 28,193 shares due to the exercise of employee warrants. The increase corresponds to approximately 0.04% of the company's share capital, and the proceeds to the company are approximately DKK 29.3 million.

AbbVie reported strong Q2 results, beating estimates for earnings and sales. The company's ex-Humira drugs, such as Rinvoq and Skyrizi, performed well, offsetting the decline in Humira sales. AbbVie raised its 2024 guidance for earnings and sales, driven by the strong performance of its newer drugs.